GLPwatch
Development of Cagrilintide, a Long-Acting Amylin Analogue.
J Med Chem · 2021
Last updated 2026-05-28Researchers developed cagrilintide, a long-acting version of the hormone amylin, to address challenges with stability and dosing. Unlike pramlintide, which requires three daily injections, cagrilintide is designed for less frequent dosing. In clinical trials, cagrilintide has led to significant weight loss when used alone or combined with the GLP-1 drug semaglutide.
AI summary of the abstract below.
| Journal | J Med Chem, 2021 |
|---|---|
| Citations | 99 |
| Relative citation ratio | 6.88 |
| NIH percentile | 95 |
| Molecules | cagrilintide |
Abstract
A hallmark of the pancreatic hormone amylin is its high propensity toward the formation of amyloid fibrils, which makes it a challenging drug design effort. The amylin analogue pramlintide is commercially available for diabetes treatment as an adjunct to insulin therapy but requires three daily injections due to its short half-life. We report here the development of the stable, lipidated long-acting amylin analogue cagrilintide () and some of the structure-activity efforts that led to the selection of this analogue for clinical development with obesity as an indication. Cagrilintide is currently in clinical trial and has induced significant weight loss when dosed alone or in combination with the GLP-1 analogue semaglutide.
Verbatim abstract via PubMed 34288673 ↗
Related research
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
- Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
- Cagrilintide plus semaglutide for obesity management.
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.